375844-31-8Relevant articles and documents
Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11β-hydroxysteroid dehydrogenase type 1
Barf, Tjeerd,Vallg?rda, Jerk,Emond, Rikard,H?ggstr?m, Charlotta,Kurz, Guido,Nygren, Alf,Larwood, Vivienne,Mosialou, Erifili,Axelsson, Kent,Olsson, Rolf,Engblom, Lars,Edling, Naimie,R?nquist-Nii, Yuko,?hman, Birgitta,Alberts, Peteris,Abrahmsén, Lars
, p. 3813 - 3815 (2002)
Novel antidiabetic arylsulfonamidothiazoles are presented that exert action through selective inhibition of the 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) enzyme, thereby attenuating hepatic gluconeogenesis. The diethylamide derivative 2a was shown to potently inhibit human 11β-HSD1 (IC50 = 52 nM), whereas the N-methylpiperazinamide analogue 2b only inhibited murine 11β-HSD1 (IC50 = 96 nM). Both compounds showed >200-fold selectivity over human and murine 11β-HSD2. 2b was subsequently shown to reduce glucose levels in diabetic KKAy mice, substantiating the 11β-HSD1 enzyme as a target for the treatment of type 2 diabetes.